AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29993436 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain-invariant projection ensemble approach with a 'sampling-and-fusion' framework
Number of subjects: 0
Study 29893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard itraconazole pulse therapy (200 mg twice per day, 1 week each month for three pulses)
Number of subjects: 90
Study 29893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term pulse therapy (200 mg twice per day, 1 week each month for six pulses)
Number of subjects: 90
Study 29893422 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose and long-term pulse therapy (200 mg/d, 1 week per month for six pulses)
Number of subjects: 90
Study 26856901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 40, 80, or 120 road, rail, and/or air traffic noise events (including one noise-free control night)
Number of subjects: 69
Study 26856901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 80 noise events per night (4 exposure nights)
Number of subjects: 69
Study 26856901 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to 40, 80, or 120 road, rail, and/or air traffic noise events
Number of subjects: 69
Study 26856901 — intervention group
Group type: COMPARATOR
Intervention: Noise-free control night
Number of subjects: 69
Study 24445389 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL 0.5% levobupivacaine
Number of subjects: 90
Study 24445389 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL 2% lidocaine
Number of subjects: 90
Study 24445389 — intervention group
Group type: COMPARATOR
Intervention: 5 mL 0.9% saline (control group)
Number of subjects: 90
Study 23232203 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigation
Number of subjects: 79
Study 23232203 — intervention group
Group type: COMPARATOR
Intervention: Control (no nasal saline irrigation)
Number of subjects: 79
Study 19436684 — intervention group
Group type: EXPERIMENTAL
Intervention: General physical training (GPT); walking and stair climbing exercises; trained daily for 30 minutes for eight weeks.
Number of subjects: 16
Study 19436684 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory muscle training (IMT); targeted breathing through inspiratory resistances; trained daily for 30 minutes for eight weeks.
Number of subjects: 16
Study 17564015 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide retard (1.5 mg/day)
Number of subjects: 50
Study 17564015 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (25 mg/day)
Number of subjects: 50
Study 14757271 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 40 mg plus estradiol valerate 2 mg
Number of subjects: 50
Study 14757271 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus estradiol valerate 2 mg
Number of subjects: 50
Study 11848548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate gel (1 gr.) applied 3 times daily
Number of subjects: 40
Study 11848548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11848548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate gel (1 gr.)
Number of subjects: 40
Study 10193395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP) at pressures of 0, 5, and 10 cm H2O
Number of subjects: 11
Study 10193395 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 11
Study 8163718 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-18790 (0.05, 0.1, 0.2, or 0.4 mg/kg intravenous dose)
Number of subjects: 36
Study 8163718 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-18790 (1-hour infusion of 0.5, 1.0, 2.5, 5.0, 10.0, or 15.0 micrograms/kg/minute)
Number of subjects: 36
Study 8163718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3283919 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine, 40 mg at night
Number of subjects: 10
Study 3283919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 28822028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol tetrasodium 3% (group A)
Number of subjects: 94
Study 28822028 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate 0.1% (group B)
Number of subjects: 94
Study 27488071 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Number of subjects: 6
Study 27488071 — intervention group
Group type: COMPARATOR
Intervention: High-dose rAAV.sFlt‐1 (1 × 10 vector genomes)
Number of subjects: 6
Study 27488071 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 6
Study 24477462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 % terbinafine film-forming solution (FFS)
Number of subjects: 290
Study 22781292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rh‐Endostatin (7.5 mg/m(2), d1‐d14) with neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1)
Number of subjects: 68
Study 22781292 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant DE regimen (docetaxel: 75 mg/m(2), d1, epirubicin: 75 mg/m(2), d1) alone
Number of subjects: 68
Study 22781292 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rh‐Endostatin with neoadjuvant DE regimen
Number of subjects: 68
Study 22781292 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant DE regimen alone
Number of subjects: 68
Study 20044128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus pegylated liposomal doxorubicin (PLD) (30 mg/m(2))
Number of subjects: 61
Study 20044128 — intervention group
Group type: COMPARATOR
Intervention: Single agent carboplatin (AUC 5)
Number of subjects: 61
Study 20044128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus PLD (30 mg/m(2))
Number of subjects: 61
Study 18047753 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (7 mg/24 h)
Number of subjects: 29
Study 18047753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15883442 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy (0.5 mg cyanocobalamin, 0.8 mg folic acid, 3 mg vitamin B‐6)
Number of subjects: 209
Study 15883442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 12823149 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP) 5 mg/day o.d.
Number of subjects: 177
Study 12823149 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA 0.8 g t.d.s.
Number of subjects: 177
Study 12823149 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate (BDP)
Number of subjects: 177
Study 11938806 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary moxibustion on Shenque (Ren 8) point during radio- and chemotherapy (30 sessions).
Number of subjects: 56
Study 11938806 — intervention group
Group type: COMPARATOR
Intervention: Control group (radio- and chemotherapy without moxibustion).
Number of subjects: 56
Study 8796367 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine 16 mg day-1
Number of subjects: 6
Study 1299247 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2 adhesive and Silux Plus resin
Number of subjects: 120
Study 1299247 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenure adhesive and Perfection resin
Number of subjects: 120
Study 1299247 — intervention group
Group type: COMPARATOR
Intervention: Fuji glass ionomer (Control)
Number of subjects: 120
Study 6591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight multitufted toothbrush
Number of subjects: 24
Study 6591370 — intervention group
Group type: EXPERIMENTAL
Intervention: V-shaped toothbrush
Number of subjects: 24
Study 6591370 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight multitufted toothbrush (professionally used)
Number of subjects: 24
Study 6591370 — intervention group
Group type: EXPERIMENTAL
Intervention: V-shaped toothbrush (professionally used)
Number of subjects: 24
Study 31543976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 60
Study 31543976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29247433 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 19
Study 29247433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 27760089 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribulus terrestris 750 mg/d for 120 days
Number of subjects: 45
Study 27760089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 25456571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus prize-based contingency management (CBT + prizeCM)
Number of subjects: 60
Study 25456571 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) alone
Number of subjects: 60
Study 22333882 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital Teaching Associates (GTA) first session
Number of subjects: 100
Study 22333882 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Simulator (SIM) first session
Number of subjects: 100
Study 20179502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-limiting group (LMA intracuff pressure <44 mmHg)
Number of subjects: 200
Study 20179502 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (no intervention)
Number of subjects: 200
Study 17118950 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE programme
Number of subjects: 4196
Study 17118950 — intervention group
Group type: COMPARATOR
Intervention: Existing sex education (control group)
Number of subjects: 4196
Study 16193589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (5 mg/ml)‐epinephrine (5 microg/ml) infiltration
Number of subjects: 64
Study 16193589 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration (Control)
Number of subjects: 64
Study 12943623 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy alone (Group A, n=23)
Number of subjects: 45
Study 12943623 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radio/chemotherapy (Group B, n=22)
Number of subjects: 45
Study 12943623 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radio/chemotherapy (Group B)
Number of subjects: 45
Study 12943623 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy alone (Group A)
Number of subjects: 45
Study 11056245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 28
Study 11056245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8856711 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive listening condition
Number of subjects: 0
Study 8856711 — intervention group
Group type: EXPERIMENTAL
Intervention: Active attending condition
Number of subjects: 0
Study 1519838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) aerosol exposure at 1,000 micrograms/m3
Number of subjects: 12
Study 1519838 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) control
Number of subjects: 12
Study 6376299 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzopyrone drug (verum group)
Number of subjects: 120
Study 6376299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 29552975 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 500
Study 29552975 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy
Number of subjects: 500
Study 29133522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group in SPRINT
Number of subjects: 13502
Study 29133522 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group in SPRINT
Number of subjects: 13502
Study 29133522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group in ACCORD
Number of subjects: 13502
Study 29133522 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment group in ACCORD
Number of subjects: 13502
Study 29133522 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in SPRINT
Number of subjects: 13502
Study 29133522 — intervention group
Group type: COMPARATOR
Intervention: Visit-to-visit variability in ACCORD
Number of subjects: 13502
Study 26366789 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous levobupivacaine infiltration at 6.25mg/h for 48h
Number of subjects: 68
Study 26366789 — intervention group
Group type: COMPARATOR
Intervention: Control group (multimodal systemic analgesia without levobupivacaine)
Number of subjects: 68
Study 23436264 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (8 mg/kg)
Number of subjects: 0
Study 23436264 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab (6 mg/kg)
Number of subjects: 0
Study 20578162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 105
Study 18247163 — intervention group
Group type: EXPERIMENTAL
Intervention: CMED (cyclophosphamide, etoposide, methotrexate, and dexamethasone)
Number of subjects: 217
Study 18247163 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 217
Study 18247163 — intervention group
Group type: EXPERIMENTAL
Intervention: CMED
Number of subjects: 217
Study 18247163 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 217
Study 16340190 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (4.5 g total dose, 1 x 500 mg weekly for 3 weeks)
Number of subjects: 63
Study 16340190 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 21 days)
Number of subjects: 63
Study 12775138 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 42
Study 12775138 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine 180 mg
Number of subjects: 42
Study 12775138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10707787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous unpurged stem-cell transplantation (U)
Number of subjects: 89
Study 10707787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy followed by autologous purged stem-cell transplantation (P)
Number of subjects: 89
Study 10707787 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy control group (C)
Number of subjects: 89
Study 9392696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 761
Study 9392696 — intervention group
Group type: COMPARATOR
Intervention: Continuous lumbar epidural analgesia
Number of subjects: 761
Study 1563815 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioluminescence assay
Number of subjects: 1000
Study 1563815 — intervention group
Group type: COMPARATOR
Intervention: Dip sticks for nitrite
Number of subjects: 1000
Study 1563815 — intervention group
Group type: COMPARATOR
Intervention: Dip sticks for leucocyte esterase
Number of subjects: 1000
Study 6365007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 48
Study 6365007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 30829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin-photodynamic therapy (standard and low-dose/low-fluence protocols)
Number of subjects: 3
Study 30829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factors
Number of subjects: 3
Study 30829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoid antagonists
Number of subjects: 3
Study 30829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 3
Study 30829023 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser with varying parameters
Number of subjects: 3
Study 29236934 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-motor training
Number of subjects: 64
Study 29236934 — intervention group
Group type: COMPARATOR
Intervention: Resistance training
Number of subjects: 64
Study 27000785 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer Navigation (PN)
Number of subjects: 94
Study 27000785 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 94
Study 27000785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Surgery Unit
Number of subjects: 94
Study 27000785 — intervention group
Group type: EXPERIMENTAL
Intervention: General Cardiology Unit
Number of subjects: 94
Study 27000785 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional Unit
Number of subjects: 94
Study 27000785 — intervention group
Group type: EXPERIMENTAL
Intervention: Closer to Home Referral
Number of subjects: 94
Study 24505293 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline presence
Number of subjects: 0
Study 24505293 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific sequence of alternating correct and incorrect answers
Number of subjects: 0
Study 22932122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixivaptan (25-100 mg per day, titrated based on daily serum sodium measurements)
Number of subjects: 206
Study 22932122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Number of subjects: 206
Study 22932122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 20178572 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint crisis plan (JCP)
Number of subjects: 120
Study 20178572 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 18214021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iron rice (3.21 mg/kg Fe)
Number of subjects: 114
Study 18214021 — intervention group
Group type: COMPARATOR
Intervention: Control rice (0.57 mg/kg Fe)
Number of subjects: 114
Study 15805364 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured psychological intervention in the first days after birth
Number of subjects: 50
Study 15805364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological intervention, counseling available by hospital minister)
Number of subjects: 50
Study 11980120 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs and laser radiation (study group)
Number of subjects: 142
Study 11980120 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 142
Study 9861118 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric bupivacaine injected at 0.02 ml s‐1 (group slow, n = 30)
Number of subjects: 60
Study 9861118 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine injected at 0.25 ml s‐1 (group fast, n = 30)
Number of subjects: 60
Study 7896945 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization procedure (UVB treatment and subcutaneous nickel sulfate administration)
Number of subjects: 21
Study 7896945 — intervention group
Group type: COMPARATOR
Intervention: Control (UVB treatment only)
Number of subjects: 21
Study 2631476 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg gallopamil (G)
Number of subjects: 32
Study 2631476 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg propranolol (P)
Number of subjects: 32
Study 2631476 — intervention group
Group type: COMPARATOR
Intervention: 0.12 mg/kg Atenolol (A)
Number of subjects: 32
Study 320919 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide aerosol (800 g daily for 12 weeks)
Number of subjects: 33
Study 320919 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 33
Study 31093613 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartMouth Clinical DDS (SM)
Number of subjects: 76
Study 31093613 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine (CHX)
Number of subjects: 76
Study 31093613 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 76
Study 27029938 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (home based exercise five days/week and progressive resistance training two days/week)
Number of subjects: 55
Study 27029938 — intervention group
Group type: COMPARATOR
Intervention: Control group (home based exercise seven days/week)
Number of subjects: 55
Study 27029938 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Progressive resistance training and Control)
Number of subjects: 55
Study 26021829 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibitor (gemigliptin)
Number of subjects: 182
Study 26021829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 23892704 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 416
Study 23892704 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 416
Study 23892704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 21889413 — intervention group
Group type: EXPERIMENTAL
Intervention: WebEase (Epilepsy Awareness, Support, and Education)
Number of subjects: 148
Study 21889413 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of WebEase modules
Number of subjects: 148
Study 21889413 — intervention group
Group type: EXPERIMENTAL
Intervention: WebEase program
Number of subjects: 148
Study 21889413 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WCL)
Number of subjects: 148
Study 19438408 — intervention group
Group type: EXPERIMENTAL
Intervention: Pfannenstiel incision
Number of subjects: 165
Study 19438408 — intervention group
Group type: COMPARATOR
Intervention: Midline incision
Number of subjects: 165
Study 17720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevanac (nepafenac 0.1%)
Number of subjects: 75
Study 17720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Acular LS (ketorolac 0.4%)
Number of subjects: 75
Study 17720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Xibrom (bromfenac 0.09%)
Number of subjects: 75
Study 17720067 — intervention group
Group type: EXPERIMENTAL
Intervention: Amfenac
Number of subjects: 75
Study 16208048 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil massage
Number of subjects: 0
Study 16208048 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil massage
Number of subjects: 0
Study 16208048 — intervention group
Group type: COMPARATOR
Intervention: Placebo (powder) massage
Number of subjects: 0
Study 16208048 — intervention group
Group type: COMPARATOR
Intervention: Neurobehavioral assessment
Number of subjects: 0